GCVRZ - Sanofi

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.5000
0.0000 (0.00%)
At close: 2:05PM EDT
Stock chart is not supported by your current browser
Previous Close0.5000
Open0.5000
Bid0.0000 x 4000
Ask0.5900 x 3000
Day's Range0.5000 - 0.5002
52 Week Range0.1500 - 0.6000
Volume18,317
Avg. Volume114,585
Market Cap623.55M
Beta (3Y Monthly)0.44
PE Ratio (TTM)0.13
EPS (TTM)3.8800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis
    Yahoo Finance Video10 days ago

    Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis

    "This opioid crisis has become a fentanyl crisis," the CEO of Opiant Dr. Roger Crystal told Yahoo Finance's Alexis Christoforous. He then goes on to discuss what else the pharmaceutical company is doing to tackle the epidemic.

  • Reuters5 days ago

    Boehringer's operating income flat as integration costs weigh

    German drugmaker Boehringer Ingelheim reported on Wednesday flat operating income of 3.5 billion euros ($4 billion) for 2018, held back by the costs of integrating the animal medicines business it acquired from Sanofi. Strong revenue gains from Boeringer's diabetes drugs were partly offset by declining revenues for its top-selling inhalable lung drug Spiriva, under pressure from rival drugs. As a result, total group sales fell 3 percent last year to 17.5 billion euros ($19.8 billion), the family-owned group said.

  • Does Sanofi (EPA:SAN) Have A Good P/E Ratio?
    Simply Wall St.6 days ago

    Does Sanofi (EPA:SAN) Have A Good P/E Ratio?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a basic P/E ratio analysis to Sanofi's (EPA:SAN), to help you decide if the stock is worth further research...

  • CNBC12 days ago

    Sanofi sets a fixed price of insulin at $99 per month for some patients

    The move is a pre-emptive one as the French drugmaker is set to testify before the House Energy and Commerce Committee on the rising prices of insulin later in the day.

  • Reuters12 days ago

    Sanofi to cut U.S. insulin costs for some patients to $99 per month

    Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication. Sanofi announced the plan hours before one of its executives was set to testify before a congressional committee on the rising prices of insulin. Executives from the other leading insulin producers - Eli Lilly & Co and Novo Nordisk A/S - will also testify.

  • Benzinga24 days ago

    CDC: 44 States Still Reporting High Flu Activity

    At a time when the flu season is typically coming to a close, the Centers for Disease Control and Prevention said this week that the number of cases and related medical visits continue to be elevated. Flu season typically ranges from November to March, with flu-like illness peaking in February, the CDC said. The incidence of patients testing positive for the flu virus influenza A (H1N1), influenza A (H3N2) and influenza B are slightly increased for the most recent three-week period, with influenza A(H3) reported more frequently, according to the federal agency.

  • Sanofi (EPA:SAN): What We Can Expect From This Growth Stock
    Simply Wall St.26 days ago

    Sanofi (EPA:SAN): What We Can Expect From This Growth Stock

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Sanofi's (EPA:SAN) earnings update on 31 December 2018, analyst...

  • What's Next for Lexicon Pharmaceuticals?
    Motley Fool28 days ago

    What's Next for Lexicon Pharmaceuticals?

    American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.

  • Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
    Motley Fool29 days ago

    Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals

    Which stock wins in a battle between these two successful biotechs?

  • This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment
    Investor's Business Dailylast month

    This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment

    Shares of French pharmaceutical giant Sanofi dipped Friday after the FDA rejected its application for a diabetes treatment created under a partnership with Lexicon Pharmaceuticals.

  • Reuterslast month

    FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

    The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday. The decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin, should be approved as an add-on to insulin therapy. The setback comes as Sanofi works to revive declining sales from its diabetes division, and as the French drugmaker faces increasing pressure from politicians and patient advocacy groups over the rising cost of its insulin products.

  • Exclusive: Sanofi says working on CEO succession plan
    Reuterslast month

    Exclusive: Sanofi says working on CEO succession plan

    Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday. Sanofi has an age limit of 65 for its CEO. Brandicourt will be 65 in February 2021.

  • Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript

    LXRX earnings call for the period ending December 31, 2018.

  • Reuterslast month

    Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

    The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs. Shares of Regeneron closed up 2.3 percent at $412.05 on Monday. The FDA first approved the drug in 2017 and it has since been launched as a treatment for adults with moderate-to-severe atopic dermatitis, or eczema, as well as a drug for some asthma patients.

  • Reuterslast month

    Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

    The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs. The drug was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.

  • Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?
    Investor's Business Dailylast month

    Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?

    On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.

  • Benzinga2 months ago

    Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

    Biotech stocks had a fairly decent outing in February, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) adding roughly 2.7 percent for the month compared to the 3 percent gain for the S&P 500 ...

  • Reuters2 months ago

    Philippines to charge officials of Sanofi, government over dengue deaths

    The Philippine Department of Justice said on Friday it had found probable cause to indict officials from French drugmaker Sanofi and former and current Philippine health officials over a series of deaths related to a dengue vaccine. It recommended that six Sanofi officials and 14 current and former Philippine health officials be charged, including former health minister Janette Garin. Sanofi could not immediately be reached for comment.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...

  • CNBC2 months ago

    Sen. Grassley says probe of 'secretive' drug industry pricing won't stop with drugmakers

    Senate Finance Committee Chairman Chuck Grassley invites seven drugmakers to testify about drug prices. Executives from seven pharmaceutical companies — AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi — will testify Tuesday before the Senate Finance Committee.

  • Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug
    Reuters2 months ago

    Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

    Sanofi and Regeneron had stipulated that if the two Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them. Regeneron and Sanofi said in a statement they disagreed with aspects of the ruling and would seek to have it overturned.